Cecil Shikiya, DO
Family Medicine · Lancaster, CANPI 1861760977
Payments from drug & device makers
Across 218 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$721
- Novo Nordisk$574
- Boehringer Ingelheim$395
- AstraZeneca$347
- Amgen$259
- Lilly USA, LLC$204
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,007100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 52 | $721 |
| Novo Nordisk | 30 | $574 |
| Boehringer Ingelheim | 21 | $395 |
| AstraZeneca | 18 | $347 |
| Amgen(2 entities) | 13 | $259 |
| Lilly USA, LLC | 8 | $204 |
| Otsuka America Pharmaceutical, Inc. | 10 | $179 |
| AbbVie(2 entities) | 8 | $166 |
| Pfizer | 7 | $139 |
| Madrigal Pharmaceuticals | 3 | $80 |
| Biohaven Pharmaceuticals, Inc. | 5 | $79 |
| Dexcom, Inc. | 3 | $79 |
| Johnson & Johnson | 5 | $79 |
| Merck | 4 | $77 |
| Sumitomo Pharma America, Inc. | 3 | $75 |
| Phathom Pharmaceuticals, Inc. | 3 | $69 |
| Radius Health, Inc. | 2 | $62 |
| Bayer | 3 | $53 |
| Verona Pharma, Inc. | 2 | $51 |
| Gilead | 2 | $42 |
| IBSA Pharma Inc. | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $30 |
| Exact Sciences | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Abbott | 1 | $26 |
| Neurelis, Inc. | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Shield Therapeutics Inc | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
How this compares
$4,007 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 113 | $121,963 |
| EliquisApixaban | 101 | $63,922 |
| JanuviaSitagliptin Phosphate | 45 | $46,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $45,846 |
| TrulicityDulaglutide | 28 | $44,878 |
| RybelsusSemaglutide | 29 | $38,753 |
| TradjentaLinagliptin | 38 | $36,387 |
| MounjaroTirzepatide | 34 | $34,590 |
| OzempicSemaglutide | 35 | $31,593 |
| LinzessLinaclotide | 32 | $23,434 |
| Repatha SureclickEvolocumab | 18 | $21,536 |
| XareltoRivaroxaban | 14 | $19,522 |
| MyrbetriqMirabegron | 38 | $18,406 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $15,480 |
| FarxigaDapagliflozin Propanediol | 17 | $13,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $395 | $158,350151 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $204 | $79,46862 claims |
| Novo NordiskRybelsus, Ozempic | $574 | $70,34764 claims |
| PfizerEliquis | $139 | $63,922101 claims |
| MerckJanuvia, Janumet | $77 | $62,36457 claims |
| GSKTrelegy Ellipta | $721 | $45,84653 claims |
| AbbVieLinzess | $166 | $23,43432 claims |
| Johnson & JohnsonXarelto | $79 | $19,52214 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $18,40638 claims |
| AstraZenecaFarxiga | $347 | $13,52817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Lancaster
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.